BIOA
Bioage Labs Inc
NASDAQ · Pharmaceuticals
$20.73
+0.75 (+3.75%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 148.13M | 155.08M | 129.49M |
| Net Income | 34.83M | 38.64M | 27.42M |
| EPS | — | — | — |
| Profit Margin | 23.5% | 24.9% | 21.2% |
| Rev Growth | -6.9% | -7.9% | +7.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 328.55M | 257.43M | 288.63M |
| Total Equity | 366.54M | 347.27M | 354.51M |
| D/E Ratio | 0.90 | 0.74 | 0.81 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 58.57M | 58.31M | 46.56M |
| Free Cash Flow | 41.37M | 59.47M | 31.55M |